Compare PPG Industries, Inc. (PPG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs Summit Therapeutics Inc — how do they compare? PPG Industries, Inc. trades at $117.3 (market cap $25.79B), while Summit Therapeutics Inc trades at $14.78 (market cap $11.34B). The key difference: PPG Industries, Inc. is far larger — about 2.3× Summit Therapeutics Inc's market cap, and PPG Industries, Inc. pays a 2.56% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PPG | SMMT | |
|---|---|---|
Market Cap | $25.79B | $11.34B |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $29.32 |
52-Week Low | $94.34 | $13.05 |
Enterprise Value | $31.90B | $10.76B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG Industries trades at $115.71, down 1.41% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 results with $15.88B revenue and $1.58B net income, and recently raised its dividend to $0.74 per share, reflecting confidence in cash flow. Analyst consensus is bullish with a $132.20 price target, though Q2 2026 earnings due July 28 are key for near-term direction.
The outlook is positive given solid profitability and dividend growth, but risks include economic sensitivity and debt levels. Upside potential exists if Q2 earnings beat expectations, while a miss could pressure the stock. The current valuation at a P/E of 16.58 appears reasonable relative to historical performance.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
